In a significant development for cancer care in India, Immuneel Therapeutics has successfully attained the country’s first documented long-term remission in individuals with aggressive blood cancers using a domestically produced CAR T-cell therapy. The innovative therapy, known as Varnimcabtagene autoleucel (IMN-003A), was administered within the IMAGINE Phase 2 clinical trial. Notably, seven patients treated in 2022 for relapsed or refractory CD19-positive B-cell Non-Hodgkin Lymphoma have sustained a progression-free status for over two years, marking a breakthrough in managing this fast-growing and treatment-resistant form of cancer.
The clinical trial yielded impressive results with no severe side effects reported, showcasing the therapy’s efficacy and safety profile. Key outcomes from the study include an 83% response rate at 90 days, an 83% complete response rate, and a one-year response rate of 50%. Notably, there were no instances of severe neurotoxicity or patients requiring ICU admissions. This success underscores the potential of CAR T-cell therapy in revolutionizing cancer treatment.
The trial was conducted at renowned medical centers in India, including Narayana Health-Mazumdar Shaw Medical Centre in Bengaluru, Apollo Cancer Centre in Chennai, and PGIMER in Chandigarh. The collaboration among these institutions has played a vital role in achieving groundbreaking outcomes and establishing India as a player in cutting-edge personalized cancer treatments. Kiran Mazumdar-Shaw, Co-Founder and Board Director of Immuneel, emphasized how this achievement sets a global standard in healthcare innovation and signifies the importance of tailoring solutions to local needs.
This milestone not only marks a significant advancement in cancer care within India but also positions the country on the global stage of pioneering cancer therapies. The success of the Made-in-India CAR T-cell therapy offers new hope to patients facing limited treatment options. It showcases the potential of local innovations to meet international standards and addresses the critical need for effective cancer treatments tailored to individual patients.
Key Takeaways:
– Immuneel Therapeutics achieves India’s first long-term cancer remission with CAR T-cell therapy, marking a milestone in the country’s cancer care landscape.
– The Varnimcabtagene autoleucel therapy demonstrates impressive outcomes with an 83% response rate at 90 days and a 50% one-year response rate, highlighting its efficacy.
– The absence of severe side effects in the clinical trial underscores the safety and potential of CAR T-cell therapy in treating aggressive blood cancers.
– Collaboration among medical centers in Bengaluru, Chennai, and Chandigarh has been pivotal in achieving globally benchmarked outcomes and establishing India as a hub for innovative cancer treatments.
Read more on daijiworld.com